Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Role of Nk and Nkt Cells in the Pathogenesis and Improvement of Multiple Sclerosis Following Disease-Modifying Therapies Publisher



Ahmadi A1 ; Fallah Vastani Z1 ; Abounoori M2 ; Azizi M3 ; Labanimotlagh A4 ; Mami S5 ; Mami S5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Student Research Committee, Department of Laboratory Sciences, Faculty of Allied Medical Sciences, Ilam University of Medical Sciences, Ilam, Iran
  2. 2. Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
  3. 3. Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Pulmonary Immunology, The University of Texas Health Science Center at Tyler, Texas, United States
  5. 5. Department of laboratory and clinical science, faculty of veterinary medicine, Ilam University, Ilam, Iran
  6. 6. Department of Immunology, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran

Source: Health Science Reports Published:2022


Abstract

Background: Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system (CNS) that T cells become autoreactive by recognizing CNS antigens. Both innate and adaptive immune systems are involved in the pathogenesis of MS. In recent years, the impact of innate immune cells on MS pathogenesis has received more attention. CD56bright NK cells, as an immunoregulatory subset of NK cells, can increase the production of cytokines that modulate adaptive immune responses, whereas CD56dim NK cells are more active in cytolysis functions. These two main subsets of NK cells may have different effects on the onset or progression of MS. Invariant NKT (iNKT) cells are other immune cells involved in the control of autoimmune diseases; however, variant NKT (vNKT) cells, despite limited information, could play a role in MS remission via an immunoregulatory pathway. Aim: We aimed to evaluate the influence of MS therapeutic agents on NK and NKT cells and NK cell subtypes. Materials and Methods: The possible mechanism of each MS therapeutic agent has been presented here, focusing on the effects of different disease-modifying therapies on the number of NK and NKT subtypes. Results: Expansion of CD56bright NK cells, reduction in the CD56dim cells, and enhancement in NKT cells are the more important innate immune cells alterations following the disease-modifying therapies. Conclusion: Expansion of CD56bright NK cells or reduction in the CD56dim cells has been associated with a successful response to different treatments in MS. iNKT and vNKT cells could have beneficial effects on MS improving. It seems that they are enhanced due to some of MS drugs, leading to disease improvement. However, a reduction in the number of NKT cells could be due to the adverse effects of some of MS drugs on the bone marrow. © 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC.
Related Docs
View other Related Docs
1. The Frequencies of Peripheral Blood Cd5+Cd19+ B Cells, Cd3−Cd16+Cd56+ Nk, and Cd3+Cd56+ Nkt Cells and Serum Interleukin-10 in Patients With Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder, Allergy, Asthma and Clinical Immunology (2022)
2. Therapeutic Targeting of Chemokines and Chemokine Receptors in Multiple Sclerosis: Opportunities and Challenges, CNS and Neurological Disorders - Drug Targets (2018)
3. The Role of Immune Regulatory Molecules in Multiple Sclerosis, Journal of Neuroimmunology (2019)
4. Flip-Flops of Natural Killer Cells in Autoimmune Diseases Versus Cancers: Immunologic Axis, Journal of Cellular Physiology (2019)
5. Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy, Cell Journal (2017)
6. The Role of Distinct Subsets of Macrophages in the Pathogenesis of Ms and the Impact of Different Therapeutic Agents on These Populations, Frontiers in Immunology (2021)
7. Il-23 Plasma Level Measurement in Relapsing Remitting Multiple Sclerosis (Rrms) Patients Compared to Healthy Subjects, Immunological Investigations (2015)
8. Il-27 Plasma Level in Relapsing Remitting Multiple Sclerosis Subjects: The Double-Faced Cytokine, Journal of Immunoassay and Immunochemistry (2016)
Experts (# of related papers)
View all Related Experts
Masoud Etemadifar (34)
Vahid Shaygannejad (25)
Other Related Docs
9. Autologous Hematopoietic Stem-Cell Transplantation in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Neurology and Therapy (2022)
10. The Levels of Soluble Forms of Cd21 and Cd83 in Multiple Sclerosis, Journal of Neuroimmunology (2018)
11. Serum Level of Interleukin 36 in Patients With Multiple Sclerosis, Journal of Immunoassay and Immunochemistry (2018)
12. Evaluation of Soluble Human Leukocyte Antigen-G (Shla-G) Isoforms and Regulatory T Cells in Relapsing-Remitting Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2015)
13. Evaluating the Effects of Epigallocatechin-3-Gallate on Hif-1Α Protein and Rorc Gene Expression in Peripheral Blood Mononuclear Cells in Patients With Multiple Sclerosis, Basic and Clinical Neuroscience (2021)
14. A Novel Approach to Discriminate Subgroups in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2016)
15. Comparison of Follicular T Helper Cells, Monocytes, and T Cells Priming Between Newly Diagnosed and Rituximab-Treated Ms Patients and Healthy Controls, Research in Pharmaceutical Sciences (2022)
16. Interleukin-33 Plasma Levels in Patients With Relapsing-Remitting Multiple Sclerosis, Biomolecular Concepts (2017)
17. Multiple Sclerosis: Clinical Features, Pathophysiology, Neuroimaging and Future Therapies, Future Neurology (2009)
18. Increased Serum Level of Il-37 in Patients With Multiple Sclerosis and Neuromyelitis Optica, Acta Neurologica Belgica (2015)
19. Th1, Th2 and Th17 Cytokine Profile in Patients With Multiple Sclerosis Following Treatment With Rapamycin, Iranian Journal of Immunology (2016)
20. Can Plasma Exchange Therapy Induce Regulatory T Lymphocytes in Multiple Sclerosis Patients?, Clinical and Experimental Immunology (2012)
21. Targeting Immune Checkpoints: How to Use Natural Killer Cells for Fighting Against Solid Tumors, Cancer Communications (2023)
22. Immune-Dysregulation Harnessing in Myeloid Neoplasms, Cancer Medicine (2024)
23. Lncrnas Associated With Multiple Sclerosis Expressed in the Th1 Cell Lineage, Journal of Cellular Physiology (2019)
24. The Comparative Analysis of Serum Levels of Midkine in Patients With Multiple Sclerosis and Control Group, Journal of Isfahan Medical School (2013)
25. Evaluation of Edaravone Effects on the Differentiation of Human Adipose Derived Stem Cells Into Oligodendrocyte Cells in Multiple Sclerosis Disease in Rats, Life Sciences (2021)
26. Immunoregulatory Effects of Silymarin on Proliferation and Activation of Th1 Cells Isolated From Newly Diagnosed and Ifn-ß 1B -Treated Ms Patients, Inflammation (2019)
27. Prognostic Value of Intrathecal Igg Synthesis in Multiple Sclerosis: A Study in 54 Patients, Tehran University Medical Journal (2008)
28. Expression of Chemokine Receptors on Th1/Th2 Cd4+ Lymphocytes in Patients With Multiple Sclerosis, Iranian Journal of Immunology (2011)
29. Anti-Cd20 Therapies for Pediatric-Onset Multiple Sclerosis: A Systematic Review, Multiple Sclerosis and Related Disorders (2024)
30. Immune System Changes During Covid-19 Recovery Play Key Role in Determining Disease Severity, International Journal of Immunopathology and Pharmacology (2020)
31. Multiple Sclerosis: Pathophysiology, Clinical Features, Diagnosis, and Management, Neuroinflammation (2011)
32. Characterizing the Immune Responses of Those Who Survived or Succumbed to Covid-19: Can Immunological Signatures Predict Outcome?, Cytokine (2021)
33. Connection of Mir-185 and Mir-320A Expression Levels With Response to Interferon-Beta in Multiple Sclerosis Patients, Multiple Sclerosis and Related Disorders (2020)
34. Apamin Administration Impact on Mir-219 and Mir-155-3P Expression in Cuprizone Induced Multiple Sclerosis Model, Molecular Biology Reports (2020)
35. Therapeutic Plasma Exchange May Adjust Il-6 and Tgf-Β Signals in Relapsed Ms Patients Peripheral Blood, Journal of Clinical Apheresis (2020)
36. Investigating the Dynamic Interplay Between Cellular Immunity and Tumor Cells in the Fight Against Cancer: An Updated Comprehensive Review, Iranian Journal of Blood and Cancer (2024)
37. Evaluation of the Expressed Mir‑129 and Mir‑549A in Patients With Multiple Sclerosis, Advanced Biomedical Research (2021)
38. Current Advances in Stem Cell Therapy in the Treatment of Multiple Sclerosis, Reviews in the Neurosciences (2023)
39. Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies, Neurology: Neuroimmunology and NeuroInflammation (2024)
40. An Integrated Bioinformatics Analysis of the Potential Regulatory Effects of Mir-21 on T-Cell Related Target Genes in Multiple Sclerosis, Avicenna Journal of Medical Biotechnology (2021)
41. Elevated Serum Level of Il-4 in Neuromyelitis Optica and Multiple Sclerosis Patients, Journal of Immunoassay and Immunochemistry (2019)
42. Cytokine Gene Expression in Newly Diagnosed Multiple Sclerosis Patients, Iranian Journal of Allergy, Asthma and Immunology (2015)
43. Cytomegalovirus Seroposivity in Iranian Multiple Sclerosis: A Randomized Case-Control Study, Pakistan Journal of Medical Sciences (2012)
44. Interferon-Beta-1Beta Protects Against Multiple Sclerosis-Induced Endothelial Cells Apoptosis, Frontiers in Bioscience - Elite (2012)
45. Chlamydia Pneumoniae Seropositivity in Iranian Patients With Multiple Sclerosis: A Pilot Study; [Obecnosc Przeciwcial Przeciw Chlamydia Pneumoniae Wsrod Iranskich Chorych Na Stwardnienie Rozsiane: Badanie Pilotazowe], Neurologia i Neurochirurgia Polska (2011)
46. Biased Treg/Th17 Balance Away From Regulatory Toward Inflammatory Phenotype in Relapsed Multiple Sclerosis and Its Correlation With Severity of Symptoms, Journal of Neuroimmunology (2013)
47. The Effect of Plasma Exchange on the Expression of Foxp3 and Rorc2 in Relapsed Multiple Sclerosis Patients, Iranian Journal of Immunology (2015)
48. Advances in Natural Killer Cell Therapies for Breast Cancer, Immunology and Cell Biology (2023)
49. Revisiting the Antiviral Theory to Explain Interferon-Beta's Effectiveness for Relapsing Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2022)
50. Identification of Potential Biomarkers in the Peripheral Blood Mononuclear Cells of Relapsing–Remitting Multiple Sclerosis Patients, Inflammation (2022)